TrialBlood2014

Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma.

Heinz Ludwig et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.